jetcityimage/iStock Editorial via Getty Images
Sales of Eli Lilly’s (NYSE:LLY) Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the country following its commercial rollout in late March, Bloomberg News reported on Saturday.
Citing data from India-based market analysis firm Pharmarack Technologies, the publication said Lilly (NYSE:LLY) recorded ₹126M ($1.5M) worth of Mounjaro sales last month. That figure included ₹75M sales of the drug’s 5mg version, indicating over a twofold rise, and ₹51M sales of its 2.5mg version.
“The patient number may have actually doubled” over the period, noted Pharmarack Vice President Sheetal Sapale, and the demand for the GLP-1 drug should continue to rise with the 5mg version being prescribed to patients after four weeks on the 2.5mg starting dose.
The Indiana-based drugmaker gained a first-mover advantage in India’s fast-expanding obesity market when it launched Mounjaro 2.5 mg and 5 mg vials at 3,500 rupees ($40.50) and 4,375 rupees ($50.63), respectively, early this year.
Its rival Novo Nordisk (NVO) has yet to roll out its popular weight loss therapy semaglutide in India, the world’s most populous country, where nearly 100M adults live with obesity.
More on Eli Lilly
- Eli Lilly: If You Don’t Buy On Weight Loss Promise Now, You Probably Never Will
- Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
- Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk’s Struggle
- Lack of permanent director sowing uncertainty at CDC – report
- Eli Lilly, Camurus in major deal to develop obesity, diabetes drugs